Medical Ethics & Regulation

Overview

Medicine is a profession granted extraordinary privileges — the power to cut, to prescribe, to experiment, to withhold information, to declare death. With these privileges come obligations: to do no harm, to act in the patient's best interest, to maintain confidentiality, and to practice within competence. In India, these ethical obligations are enforced through a complex web of statutes, regulatory bodies, and judicial precedents that have evolved over seven decades, often in response to scandal, tragedy, or technological change.

The regulatory landscape spans medical education (National Medical Commission), drug pricing (NPPA), research ethics (ICMR and CDSCO), reproductive technology (Surrogacy Act), organ transplantation (THOA), and civil and criminal liability for negligence. It is a system under constant strain: underfunded regulators, overlapping jurisdictions, chronic judicial delays, and a power imbalance between patients and providers that makes accountability difficult. Understanding this architecture is essential not only for aspirants preparing for civil service examinations but for any citizen who may one day find themselves vulnerable in a hospital ward.

Medical Regulation: From MCI to NMC

For six decades, the Medical Council of India (MCI) regulated medical education and practitioner registration. By the 2010s, it had become synonymous with corruption: capitation fees, fake colleges, examiner leaks, and political patronage. A parliamentary standing committee described it as a "den of corruption." In 2018, the Supreme Court ordered the dissolution of the MCI and the formation of a Board of Governors. The National Medical Commission (NMC) Act, 2019 replaced the MCI entirely, creating a new statutory framework intended to be more transparent, accountable, and responsive.

• NMC structure: The NMC comprises 33 members, including ex-officio government representatives, elected medical practitioners, and nominees from the Ministry of Health. It has four autonomous boards: Under-Graduate Medical Education, Post-Graduate Medical Education, Medical Assessment and Rating, and Ethics and Medical Registration.
• Key reforms: The NMC introduced the National Exit Test (NEXT) as a common final-year MBBS examination and licensing test, replacing the fragmented state-level exams. It standardized fees for 50% of seats in private medical colleges and introduced a national register of medical practitioners (National Medical Register) to track qualifications and disciplinary actions.
• Community Health Providers: The most controversial provision of the NMC Act permits the licensing of mid-level practitioners — Community Health Providers (CHPs) — to practice modern medicine in primary care settings after a 6-month bridge course. The Indian Medical Association (IMA) opposed this as "mixopathy," arguing it endangers patient safety. Defenders cite the severe doctor shortage in rural areas.
• Challenges: The NMC's capacity to inspect and rate colleges remains limited; in 2023, over 100 medical colleges were denied recognition for deficiencies in faculty, infrastructure, or patient load. Corruption in medical education has not disappeared — it has adapted to new institutional forms.

Clinical Trials Regulation

India emerged as a major hub for global clinical trials in the 2000s, attracting pharmaceutical companies with its large treatment-naïve population, diverse genetic pool, and low costs. This boom came at a cost: scandals involving unethical trials on vulnerable populations — tribals, orphans, mentally ill patients — without informed consent led to public outcry and regulatory tightening.

• Regulatory framework: Clinical trials are regulated by the Central Drugs Standard Control Organization (CDSCO) under the Drugs and Cosmetics Act, 1940. The New Drugs and Clinical Trials Rules, 2019 streamlined approval processes while strengthening ethics requirements. Every trial must be approved by an Institutional Ethics Committee (IEC) and registered with the Clinical Trials Registry – India (CTRI).
• Informed consent: The 2019 Rules mandate audio-video recording of the informed consent process for vulnerable participants (pregnant women, mentally ill persons, prisoners, children, and economically disadvantaged). Compensation for trial-related injury or death must be provided within a specified timeframe.
• Post-trial access: A significant ethical advance in the 2019 Rules is the requirement for sponsors to provide post-trial access to successful investigational drugs for trial participants — addressing the exploitation concern that poor populations were used to develop drugs they could never afford.
• Remaining gaps: Despite reforms, enforcement remains weak. A 2022 parliamentary committee found that CDSCO lacked the staff and infrastructure to monitor ongoing trials effectively. Many ethics committees are rubber stamps, and adverse event reporting is incomplete.

Drug Pricing and NPPA

India is the "pharmacy of the world" — but within its borders, essential medicines remain unaffordable for millions. The National Pharmaceutical Pricing Authority (NPPA), established in 1997, regulates the prices of medicines and medical devices listed under the National List of Essential Medicines (NLEM).

• Drug Price Control Orders (DPCO): The DPCO 2013 brought 348 medicines (and their formulations) under price control using a market-based pricing formula (average price of brands with >1% market share + 16% retail margin). In 2022, the NLEM was expanded to 384 medicines, including anti-cancer drugs, antibiotics, and cardiac medicines.
• Medical devices: The NPPA has capped prices of stents (2017) and knee implants (2017), reducing costs by 70–85%. This was hailed as pro-patient but criticized by industry for stifling innovation and reducing product quality. The government has since moved to regulate more devices, including oxygen concentrators and pulse oximeters during COVID-19.
• Jan Aushadhi scheme: The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) provides generic medicines at 50–90% below market rates through dedicated Janaushadhi Kendras. As of 2024, over 10,000 kendras are operational, but their penetration in rural areas remains limited.
• Tension: The pharmaceutical industry argues that price controls reduce R&D investment and encourage the production of substandard generics. Public health advocates counter that profit margins on essential medicines are excessive and that access must override industry preference.

Surrogacy Regulation

India was once the global capital of commercial surrogacy, a multi-billion-dollar industry catering to foreign couples, celebrities, and infertile Indians. The lack of regulation led to exploitation of poor women, abandonment of children with disabilities, and unethical brokerage practices. After years of legislative delay, the Surrogacy (Regulation) Act, 2021 was enacted, banning commercial surrogacy and permitting only altruistic surrogacy for Indian couples.

• Key provisions: Surrogacy is permitted only for legally married Indian couples who have been married for at least 5 years and are unable to conceive. The surrogate must be a close relative (married, aged 25–35, with at least one biological child). No payment beyond medical expenses and insurance coverage is permitted. Foreigners, NRIs, same-sex couples, single parents, and live-in partners are excluded.
• Regulatory bodies: National and State Surrogacy Boards oversee implementation. Surrogacy clinics must be registered, and every arrangement must be approved by the appropriate authority.
• Criticism: Feminist and human rights groups have criticized the Act for being patriarchal and exclusionary. The requirement that the surrogate be a "close relative" forces women into familial pressure and eliminates the possibility of informed, arms-length consent. The exclusion of single parents, same-sex couples, and foreigners discriminates against non-traditional family structures. The ban on commercial surrogacy has driven the practice underground, potentially increasing exploitation.
• Assisted Reproductive Technology (ART) Act, 2021: Passed alongside the Surrogacy Act, this regulates IVF clinics, sperm/egg donation, and embryo research. It mandates that donor identity be kept confidential and that children born through ART have the same rights as biological children.

Organ Transplantation

India performs the second-largest number of organ transplants in the world (after the United States), yet the gap between demand and supply is catastrophic: an estimated 500,000 people die annually from organ failure because of the shortage. This shortage has fuelled a thriving black market in kidneys, livers, and corneas, disproportionately exploiting the poor.

• Transplantation of Human Organs Act (THOA), 1994: THOA legalized brain-stem death, established authorization committees to approve living donor transplants, and prohibited commercial dealing in organs. It was amended in 2011 and 2014 to tighten penalties, expand the definition of "near relative," and regulate tissue banks.
• Brain-stem death: Despite being legally recognized for nearly three decades, brain-stem death certification remains rare outside major cities. Religious and cultural resistance, combined with lack of ICU infrastructure, means that most potential deceased donors are lost. India has a deceased donation rate of ~0.5 per million population, compared to 30–40 in Spain and the US.
• Organ trafficking: The 2008 "Gurgaon kidney scandal" — where a doctor ran an illegal kidney transplant racket targeting poor labourers — exposed systemic failures in authorization committee oversight. Similar scandals have recurred, indicating that the regulatory framework is porous.
• NOTTO: The National Organ and Tissue Transplant Organisation (NOTTO) maintains the national waiting list, allocates organs, and promotes deceased donation. Green corridors (traffic-free routes) have been established in major cities to transport organs rapidly. However, equitable distribution remains a challenge — wealthy patients can access transplants faster through private hospitals and living donors.

Medical Negligence

When medical care causes harm, the patient may seek redress through civil liability (tort), criminal prosecution, or consumer protection forums. Indian jurisprudence on medical negligence has evolved through landmark Supreme Court judgments that have defined the standard of care, the burden of proof, and the limits of doctor liability.

• Civil liability: Under the law of torts, a doctor is liable if they fail to exercise the reasonable degree of skill and care expected of a professional in their field. The Supreme Court in Jacob Mathew v. State of Punjab (2005) held that doctors should not be prosecuted for criminal negligence unless the negligence is "gross" or "reckless." This was a protective ruling intended to prevent defensive medicine, but it has also made criminal conviction of negligent doctors rare.
• Consumer Protection: The Consumer Protection Act, 2019 (and its predecessor, the 1986 Act) allows patients to file complaints for deficient services in medical establishments. The National Consumer Disputes Redressal Commission (NCDRC) and state commissions have awarded significant compensation for wrongful death, botched surgeries, and misdiagnosis. However, cases take years to resolve, and the compensation amounts are often modest compared to the harm suffered.
• Professional discipline: State Medical Councils (and now the NMC's Ethics and Medical Registration Board) can suspend or cancel a doctor's license for professional misconduct. However, disciplinary action is rare and slow; the MCI was notorious for shielding influential doctors.
• No-fault liability: India does not have a comprehensive no-fault compensation scheme for medical injuries. Proposals for such schemes — which would compensate patients without requiring proof of negligence — have been discussed but not implemented, leaving the burden of litigation on patients who are often least equipped to bear it.

Sources